7 results about "Differentiation Agents" patented technology

The invention belongs to the field of biomedical materials and manufacturing thereof, and discloses a composite 3D printing stent with a time sequence regulation blood vessel and bone tissue regeneration function as well as a preparation method and application of the composite 3D printing stent. The method comprises the following steps: respectively loading an osteogenesis inducer and a vascular induced differentiation agent into two carrier materials with different degradation rates, and carrying out 3D printing and gel coating modification according to a reverse sequence of a physiological repair process of carrying out vascularization first and then carrying out osteogenesis to form a composite 3D printing stent of which the inner layer is loaded with the osteogenesis inducer and the outer layer is loaded with the vascular induced differentiation agent. After the composite 3D printing stent is implanted into a body, according to different degradation rates of the composite material, the repair and regeneration process of vascularization and osteogenesis is realized in a manner of degrading the gel coating and degrading the 3D printing stent, and the composite 3D printing stent has good living compatibility, biological activity and mechanical properties, and has good application prospects. The material can be used as a biomedical material for repairing or treating bone defects or self-repairing, and has a good application prospect in treatment and self-repairing of bone defects.

To provide a new technique for inhibiting formation of pigmented spots.SOLUTION: The present invention provides a pigmented spot formation inhibitor including vitamin B6 as an active ingredient.SELECTED DRAWING: None

Provided is a differentiation agent consisting essentially of SOX9 for generating oligodendrocyte progenitor cells (OPCs) from pluripotent stem cells (PSCs). Also provided are methods of generating PSCs and methods of using PSCs to generate OPCs and oligodendrocytes.SOLUTION: A method comprising culturing pluripotent stem cells (PSCs) to produce a population of cells comprising oligodendrocyte progenitor cells (OPCs), wherein the PSCs express engineered nucleic acids encoding SOX9 at a level sufficient to differentiate the PSCs into OPCs in the absence of other transcription factors encoded by the engineered nucleic acids.SELECTED DRAWING: Figure 2C

The present application relates to the use of a VRAC modulator of formula I or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of cancer in combination with an anti-cancer therapeutic agent, wherein the anti-cancer therapeutic agent is selected from the group consisting of topoisomerase inhibitors, antihormones, alkylating agents, antimetabolites, anti-tumor antibiotics, corticosteroids, targeted anti-cancer therapies, differentiation agents, and immunotherapies. # imgabs0 #

Provided herein is a differentiation agent that consists essentially of SOX9 for the production of oligodendrocyte progenitor cells (OPCs) from pluripotent stem cells (PSC). Also provided herein are methods of producing the PSCs and methods of using the PSCs to produce OPCs and oligodendrocytes.

The invention belongs to the field of new auxiliary materials and new dosage forms of pharmaceutical preparations, and particularly relates to a core-shell structure sequential drug release system for cascade deep penetration and induced differentiation treatment, construction of the core-shell structure sequential drug release system and application of the core-shell structure sequential drug release system in a drug delivery system. The system is of a shell-core structure, an inner core is nanoparticles which encapsulate an induced differentiation agent and have hypoxia response capability, and a shell is an acid response reversible polymer loaded with chemotherapeutic drugs. According to the invention, a pulse drug release strategy is utilized to overcome penetration obstacles of solid tumors, programmed drug release is carried out aiming at heterogeneity distribution of different cells in the tumors, a tumor microenvironment characterized by chemotherapy drug resistance and immune escape is effectively remodeled, and comprehensive inhibition of the tumors is realized.

Provided herein is a differentiation agent that consists essentially of SOX9 for the production of oligodendrocyte progenitor cells (OPCs) from pluripotent stem cells (PSCs). Also provided herein are methods of producing the PSCs and methods of using the PSCs to produce OPCs and oligodendrocytes.